 Jazz Pharmaceuticals plc NASDAQ: JAZZ has acquired exclusive global development and commercialization rights to Werewolf Therapeutics Incs NASDAQ: HOWL WTX-613. WTX-613 is a differentiated, conditionally-activated interferon-alpha IFNα INDUKINE molecule. 